Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group
By M. Nadim, John A. Kellum, Andrew Davenport, F. Wong, C. Davis, N. Pannu, Ashita Tolwani, R. Bellomo, Yuri S. Genyk. Critical Care, 2012
5,149 citations recorded by the source corpus.
IntroductionRenal dysfunction is a common complication in patients with end-stage cirrhosis. Since the original publication of the definition and diagnostic criteria for the hepatorenal syndrome (HRS), there have been major advances in our understanding of its pathogenesis. The prognosis of patients with cirrhosis who develop HRS remains poor, with a median survival without liver transplantation of less than six months. However, a number of pharmacological and other therapeutic strategies have now become available which offer the ability to prevent or treat renal dysfunction more effectively in this setting. Accordingly, we sought to review the available evidence, make recommendations and delineate key questions for future studies.MethodsWe undertook a systematic review of the literature using Medline, PubMed and Web of Science, data provided by the Scientific Registry of Transplant Recipients and the bibliographies of key reviews. We determined a list of key questions and convened a two-day consensus conference to develop summary statements via a series of alternating breakout and plenary sessions. In these sessions, we identified supporting evidence and generated recommendations and/or directions for future research.ResultsOf the 30 questions considered, we found inadequate evidence for the majority of questions and our recommendations were mainly based on expert opinion. There was insufficient evidence to grade three questions, but we were able to develop a consensus definition for acute kidney injury in patients with cirrhosis and provide consensus recommendations for future investigations to address key areas of uncertainty.ConclusionsDespite a paucity of sufficiently powered prospectively randomized trials, we were able to establish an evidence-based appraisal of this field and develop a set of consensus recommendations to standardize care and direct further research for patients with cirrhosis and renal dysfunction.
Subfields: Hepatology, Nephrology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ff82d52493d100dff6ca4858e4b92df16f96fb22
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Nephrology
- M. Bernardi
- Aleksander Krag
- Jean-Louis Vincent
- C. Francoz
- Sean M. Bagshaw
- C. Villanueva
- J. Trebicka
- W. Laleman
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury (2013, methodology): “AKI status was classified using the RIFLE [10] or AKIN criteria [11] together as described in the recent KDIGO international guideline [6] based on the serum creatinine (sCR) and urine output (UO) available in the hospital record.”
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “Alfapump® had no effect on survival and was associated with a significantly higher incidence of serious adverse events (85.2 vs. 45.2%), mainly represented by AKI [126].”